Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Rochelle Walensky is Co-Director of the Medical PracticeEvaluation Center and, within that Center, is the Director of the Program in Epidemiology and Outcomes Research in Infectious Diseases. Dr. Walensky's HIV-related research interests include the promotion of routine HIV counseling, testing and referral and the economic evaluation of alternative HIV testing and treatment policies. Dr. Walensky has published work on the impact of routine HIV screening, on the clinical and cost-effectiveness of HIV vaccines of varying efficacies, on the impact of generic antiretroviral, and on the preventive impact of early antiretroviral therapy. Her research is conducted both in the US and abroad. Current projects include: 1) Ananalysis of the economic impact of economic incentives to promote ART retention;2) the years of life saved associated with ART in South Africa; and 3) the development of and HIV testing program in KwaZulu-Natal, South Africa and in a refugee setting in Uganda. Within the Program in Epidemiology and OutcomesResearch in Infectious Diseases, Dr. Walensky has expanded her research portfolio to include a clinical trial of documenting MRSA clearance; the cost-effectiveness of diagnostic strategies to remove of MRSA/VRE-related contact precautions; and resource utilization associated with antibiotic allergies. She welcomes the opportunity to expand clinical research within general infectious diseases.
View my most recent publications at PubMed
A new study finds that implementing the United Nations targets for HIV testing and treatment would be an expensive but ultimately very cost-effective way to increase survival, reduce the number of children orphaned by HIV, and contain the global AIDS epidemic.
A study by Massachusetts General Hospital investigators, working in collaboration with colleagues in Mozambique and South Africa, indicates that routine point-of-care CD4 testing at the time of HIV diagnosis could be cost effective in countries where health care and other resources are severely limited.
Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases.
"Treatment as prevention" – early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission – appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission.
Replacing the combination of brand-name, antiretroviral drugs currently recommended for control of HIV infection with soon-to-be-available generic medications could save the U.S. health care system almost $1 billion a year but may diminish the effectiveness of HIV treatment.
Implementing universal HIV testing and immediate antiretroviral treatment for infected individuals could have a major impact on the HIV/AIDS epidemic in Washington, DC but not halt the epidemic, which a previous report had projected.
MGH Hotline 4.2.10
Early initiation of lifesaving antiretroviral therapies should be the standard of care for all HIV-infected patients, even those in countries with limited medical and financial resources, according to a study led by researchers at MGH and the Desmond Tutu HIV Centre, University of Cape Town, South Africa.
Back to Top